moxonidine has been researched along with Obesity in 22 studies
moxonidine: structure given in first source
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty-six patients with mild hypertension were treated with moxonidine and a hypocaloric diet for 3 months, while a second normotensive group (n = 26) were followed-up with calorie restriction alone." | 9.12 | The effect of moxonidine on endothelial dysfunction in metabolic syndrome. ( Cikim, AS; Cikim, K; Ozdemir, R; Temel, I; Topal, E, 2006) |
| "Moxonidine is useful and safe for controlling arterial hypertension in obese patients." | 9.11 | Efficacy of moxonidine in the treatment of hypertension in obese, noncontrolled hypertensive patients. ( Abellán, J; de Vinuesa, SG; García-Galbis, JA; Hernández-Menárguez, F; Leal, M; Luño, J; Martínez-Pastor, A, 2005) |
| "To study whether insulin sensitivity and insulin response are altered by moxonidine treatment in obese patients with mild essential hypertension." | 9.09 | Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. ( Haenni, A; Lithell, H, 1999) |
| " In dose-response experiments, the maximal response (E(max)) was markedly reduced 18." | 5.34 | Marked insulin resistance in obese spontaneously hypertensive rat adipocytes is ameliorated by in vivo but not in vitro treatment with moxonidine. ( Ernsberger, P; Sun, Z, 2007) |
| "Moxonidine is a centrally active imidazoline receptor agonist that effectively lowers blood pressure and has been shown to have beneficial effects on lipid and carbohydrate metabolism." | 5.32 | Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study. ( Marsalek, P; Sharma, AM; Wagner, T, 2004) |
| "Twenty-six patients with mild hypertension were treated with moxonidine and a hypocaloric diet for 3 months, while a second normotensive group (n = 26) were followed-up with calorie restriction alone." | 5.12 | The effect of moxonidine on endothelial dysfunction in metabolic syndrome. ( Cikim, AS; Cikim, K; Ozdemir, R; Temel, I; Topal, E, 2006) |
| "Moxonidine is useful and safe for controlling arterial hypertension in obese patients." | 5.11 | Efficacy of moxonidine in the treatment of hypertension in obese, noncontrolled hypertensive patients. ( Abellán, J; de Vinuesa, SG; García-Galbis, JA; Hernández-Menárguez, F; Leal, M; Luño, J; Martínez-Pastor, A, 2005) |
| "To study whether insulin sensitivity and insulin response are altered by moxonidine treatment in obese patients with mild essential hypertension." | 5.09 | Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. ( Haenni, A; Lithell, H, 1999) |
| "The I1-imidazoline receptor is a specific high-affinity binding site corresponding to a functional cell-surface receptor mediating the antihypertensive actions of moxonidine and other second-generation centrally-acting agents, and may play a role in countering insulin resistance in an animal model of metabolic syndrome X." | 4.79 | The I1-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease. ( Ernsberger, P; Friedman, JE; Koletsky, RJ, 1997) |
| "The antihypertensive agent moxonidine, an imidazoline Ii-receptor agonist, also induces hypophagia and lowers body weight in the obese spontaneously hypertensive rat, but the central mediation of this action and the neuronal pathways that moxonidine may interact with are not known." | 3.70 | The effect of moxonidine on feeding and body fat in obese Zucker rats: role of hypothalamic NPY neurones. ( Bing, C; Brown, M; Kaan, E; King, P; Pickavance, L; Williams, G; Ziegler, D, 1999) |
| "The sympatholytic antihypertensive agent moxonidine, a centrally acting selective I1-imidazoline receptor modulator (putative agonist), may be beneficial in hypertensive patients with insulin resistance." | 3.69 | Antihypertensive agent moxonidine enhances muscle glucose transport in insulin-resistant rats. ( Fogt, DL; Gödicke, J; Henriksen, EJ; Jacob, S; Youngblood, EB, 1997) |
| "Amlodipine was used as the control drug." | 2.72 | Selective imidazoline agonist moxonidine in obese hypertensive patients. ( de Abreu, VG; Francischetti, EA; Sanjuliani, AF, 2006) |
| "Moxonidine has been shown to improve glucose tolerance in man, probably by two different mechanisms, i." | 2.40 | Therapy of hypertension and metabolic syndrome: today's standard and tomorrow's perspectives. ( Hansson, L, 1998) |
| " In dose-response experiments, the maximal response (E(max)) was markedly reduced 18." | 1.34 | Marked insulin resistance in obese spontaneously hypertensive rat adipocytes is ameliorated by in vivo but not in vitro treatment with moxonidine. ( Ernsberger, P; Sun, Z, 2007) |
| " Similar responses were observed after oral dosing and in lean littermates." | 1.32 | The role of I(1)-imidazoline and alpha(2)-adrenergic receptors in the modulation of glucose metabolism in the spontaneously hypertensive obese rat model of metabolic syndrome X. ( Ernsberger, P; Velliquette, RA, 2003) |
| "Using a rat model of metabolic syndrome X, we sought to separate the influence of these two receptors on glucose and lipid metabolism by using selective antagonists." | 1.32 | The role of I(1)-imidazoline receptors and alpha(2)-adrenergic receptors in the modulation of glucose and lipid metabolism in the SHROB model of metabolic syndrome X. ( Ernsberger, P; Koletsky, RJ; Velliquette, RA, 2003) |
| "Moxonidine is a centrally active imidazoline receptor agonist that effectively lowers blood pressure and has been shown to have beneficial effects on lipid and carbohydrate metabolism." | 1.32 | Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study. ( Marsalek, P; Sharma, AM; Wagner, T, 2004) |
| "Moxonidine treatment reduced fasting insulin levels by 71% in SHROB and lowered plasma free fatty acids by 25%." | 1.30 | Mechanisms of antihyperglycemic effects of moxonidine in the obese spontaneously hypertensive Koletsky rat (SHROB). ( Bedol, D; Ernsberger, P; Farrell, CJ; Friedman, JE; Ishizuka, T; Koletsky, RJ; Liu, S, 1999) |
| "Moxonidine treatment enhanced the expression of IRS-1 protein in skeletal muscle by 74% in SHROB and 40% in SHR." | 1.30 | Anti-hyperglycemic activity of moxonidine: metabolic and molecular effects in obese spontaneously hypertensive rats. ( Bedol, D; Ernsberger, P; Farrell, CJ; Friedman, JE; Ishizuka, T; Koletsky, RJ; Liu, S, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (50.00) | 18.2507 |
| 2000's | 11 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Velliquette, RA | 3 |
| Ernsberger, P | 9 |
| Mukaddam-Daher, S | 1 |
| Menaouar, A | 1 |
| El-Ayoubi, R | 1 |
| Gutkowska, J | 1 |
| Jankowski, M | 1 |
| Koletsky, RJ | 6 |
| Sharma, AM | 1 |
| Wagner, T | 1 |
| Marsalek, P | 1 |
| Abellán, J | 1 |
| Leal, M | 1 |
| Hernández-Menárguez, F | 1 |
| García-Galbis, JA | 1 |
| Martínez-Pastor, A | 1 |
| de Vinuesa, SG | 1 |
| Luño, J | 1 |
| Sanjuliani, AF | 1 |
| de Abreu, VG | 1 |
| Francischetti, EA | 1 |
| Topal, E | 1 |
| Cikim, AS | 1 |
| Cikim, K | 1 |
| Temel, I | 1 |
| Ozdemir, R | 1 |
| Sun, Z | 1 |
| Kaaja, R | 1 |
| Kujala, S | 1 |
| Manhem, K | 1 |
| Katzman, P | 1 |
| Kibarskis, A | 1 |
| Antikainen, R | 1 |
| Ylihärsilä, H | 1 |
| Erkkola, R | 1 |
| Tuomilehto, J | 1 |
| Kagota, S | 1 |
| Tada, Y | 1 |
| Kubota, Y | 1 |
| Nejime, N | 1 |
| Yamaguchi, Y | 1 |
| Nakamura, K | 1 |
| Kunitomo, M | 1 |
| Shinozuka, K | 1 |
| Rupp, H | 1 |
| Jacob, R | 1 |
| Collins, LA | 1 |
| Bedol, D | 3 |
| Friedman, JE | 4 |
| Henriksen, EJ | 1 |
| Jacob, S | 1 |
| Fogt, DL | 1 |
| Youngblood, EB | 1 |
| Gödicke, J | 1 |
| Ishizuka, T | 2 |
| Liu, S | 2 |
| Farrell, CJ | 2 |
| Hansson, L | 1 |
| Bing, C | 1 |
| King, P | 1 |
| Pickavance, L | 1 |
| Brown, M | 1 |
| Ziegler, D | 1 |
| Kaan, E | 1 |
| Williams, G | 1 |
| Haenni, A | 1 |
| Lithell, H | 1 |
2 reviews available for moxonidine and Obesity
| Article | Year |
|---|---|
The I1-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease.
Topics: Animals; Antihypertensive Agents; Binding Sites; Clonidine; Humans; Hypertension; Imidazoles; Imidaz | 1997 |
Therapy of hypertension and metabolic syndrome: today's standard and tomorrow's perspectives.
Topics: Antihypertensive Agents; Humans; Hyperlipidemias; Hypertension; Imidazoles; Insulin Resistance; Obes | 1998 |
5 trials available for moxonidine and Obesity
| Article | Year |
|---|---|
Efficacy of moxonidine in the treatment of hypertension in obese, noncontrolled hypertensive patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Diabetes Mellit | 2005 |
Selective imidazoline agonist moxonidine in obese hypertensive patients.
Topics: Adult; Amlodipine; Anthropometry; Antihypertensive Agents; Female; Hemodynamics; Humans; Hypertensio | 2006 |
The effect of moxonidine on endothelial dysfunction in metabolic syndrome.
Topics: Adult; Antihypertensive Agents; Blood Pressure Determination; Caloric Restriction; Combined Modality | 2006 |
Effects of sympatholytic therapy on insulin sensitivity indices in hypertensive postmenopausal women.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Double-Blind Method; Female; Finland | 2007 |
Moxonidine improves insulin sensitivity in insulin-resistant hypertensives.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulat | 1999 |
15 other studies available for moxonidine and Obesity
| Article | Year |
|---|---|
[Obesity and hypertension. A dangerous liaison].
Topics: Antihypertensive Agents; Humans; Hypertension; Imidazoles; Obesity; Sympatholytics | 2002 |
The role of I(1)-imidazoline and alpha(2)-adrenergic receptors in the modulation of glucose metabolism in the spontaneously hypertensive obese rat model of metabolic syndrome X.
Topics: Adrenergic alpha-2 Receptor Antagonists; Animals; Clonidine; Disease Models, Animal; Female; Glucose | 2003 |
Cardiac effects of moxonidine in spontaneously hypertensive obese rats.
Topics: Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Pressure; Female; Heart Atria; He | 2003 |
The role of I(1)-imidazoline receptors and alpha(2)-adrenergic receptors in the modulation of glucose and lipid metabolism in the SHROB model of metabolic syndrome X.
Topics: Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Benzofurans; Blood Pressure; Disease | 2003 |
Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Biomarkers; Blood Glucose; Blood Pressure; | 2004 |
Marked insulin resistance in obese spontaneously hypertensive rat adipocytes is ameliorated by in vivo but not in vitro treatment with moxonidine.
Topics: Adipocytes; Animals; Dose-Response Relationship, Drug; Female; Glucose; Hypertension; Imidazoles; In | 2007 |
Peroxynitrite is Involved in the dysfunction of vasorelaxation in SHR/NDmcr-cp rats, spontaneously hypertensive obese rats.
Topics: Acetylcholine; Amlodipine; Animals; Aorta, Thoracic; Blood Glucose; Blood Pressure; Blotting, Wester | 2007 |
Excess catecholamines and the metabolic syndrome: should central imidazoline receptors be a therapeutic target?
Topics: Animals; Antihypertensive Agents; Cardiovascular Diseases; Catecholamines; Energy Intake; Energy Met | 1995 |
Sympathetic nervous system in salt-sensitive and obese hypertension: amelioration of multiple abnormalities by a central sympatholytic agent.
Topics: Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Eating; Female; Glucos | 1996 |
Antihypertensive agent moxonidine enhances muscle glucose transport in insulin-resistant rats.
Topics: Animals; Antihypertensive Agents; Biological Transport; Blood Glucose; Body Weight; Fatty Acids, Non | 1997 |
[The significance of the sympathetic nervous system during therapy for hypertension and related pathologies. Imidazoline-I1-receptor agonists. 17th Scientific Meeting of the International Society of Hypertension. Amsterdam, June 7, 1998].
Topics: Antihypertensive Agents; Diabetes Mellitus, Type 2; Humans; Hypertension; Imidazoles; Imidazoline Re | 1998 |
Mechanisms of antihyperglycemic effects of moxonidine in the obese spontaneously hypertensive Koletsky rat (SHROB).
Topics: Animals; Antihypertensive Agents; Female; Glucose Tolerance Test; Glucose Transporter Type 4; Hypert | 1999 |
Anti-hyperglycemic activity of moxonidine: metabolic and molecular effects in obese spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Disease Models, Animal; Female; Hyperglycemia; Hypertension; Hypog | 1998 |
The effect of moxonidine on feeding and body fat in obese Zucker rats: role of hypothalamic NPY neurones.
Topics: Adipose Tissue; Animals; Anti-Obesity Agents; Antihypertensive Agents; Blood Glucose; Body Weight; C | 1999 |
Molecular pathology in the obese spontaneous hypertensive Koletsky rat: a model of syndrome X.
Topics: Animals; Anti-Obesity Agents; Carrier Proteins; Disease Models, Animal; Endocrine System; Female; Hy | 1999 |